Ahead of the upcoming DSCSA November deadline, pharma companies reimagine track and trace to tackle the US counterfeit drug landscape. Read the full article…
Although the U.S. Food and Drug Administration (FDA)’s Drug Supply Chain Security Act (DSCSA) recently granted a reprieve for one year before sanctioning pharmaceutical companies, the November 27, 2023, deadline nevertheless remains. Read the full article…
It’s a breather, not a break. The pharmaceutical industry has been gearing up for the November 27, 2023, compliance deadline for the Drug Supply Chain Security Act (DSCSA). To the casual observer, it seems as if the Food and Drug Administration (FDA) has delayed DSCSA implementation once again until November 2024. That’s not the case. Let’s unpack what’s actually going on. Read the full article…
Despite significant challenges caused by COVID-19 disruptions, the pharmaceutical track-and-trace sector has made strides in three areas to help secure the global supply chain now and well into the future. Read the full article…
In late June 2017, the U.S. Food and Drug Administration announced a one-year delay in the enforcement of the Drug and Supply Chain Security Act’s (DSCSA) requirement for manufacturers to affix or imprint product identifiers to each package or homogeneous case of product. Despite this delay, the pharmaceutical community strives to meet the original deadline. Read the full article…
